<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653470</url>
  </required_header>
  <id_info>
    <org_study_id>CA216-003</org_study_id>
    <secondary_id>2012-003232-23</secondary_id>
    <nct_id>NCT01653470</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety &amp; Tolerability of BMS-906024 in Combination With Chemotherapy &amp; to Define DLTs &amp; MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors</brief_title>
  <official_title>A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in
      combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus
      Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic
      solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DLTs = dose-limiting toxicities

      MTD = Maximum tolerated dose
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2012</start_date>
  <completion_date type="Actual">May 8, 2017</completion_date>
  <primary_completion_date type="Actual">May 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment based on reports of adverse events and clinical laboratory tests as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Up to 30 days after the last dose of study medication</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin</measure>
    <time_frame>16 time points up to first 3 cycles</time_frame>
    <description>Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Cmin) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin</measure>
    <time_frame>16 time points up to first 3 cycles</time_frame>
    <description>Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin</measure>
    <time_frame>16 time points up to first 3 cycles</time_frame>
    <description>Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve during a dosing interval of tau [AUC(TAU)] of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024)</measure>
    <time_frame>16 time points up to first 3 cycles</time_frame>
    <description>Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to the time of the last sample collected in the dosing interval [AUC(0-T)] of Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin</measure>
    <time_frame>16 time points up to first 3 cycles</time_frame>
    <description>Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state infusion concentration (Css) of 5-Fluorouracil (5-FU)</measure>
    <time_frame>16 time points up to first 3 cycles</time_frame>
    <description>Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response [as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria], best overall response (BOR), duration of response, and progression free survival (PFS) will be assessed</measure>
    <time_frame>Every 6 weeks until confirmed disease progression, death or discontinuation for other reasons (whichever comes first) [Approximately 24 months]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene mutation status of Notch activation markers as well as other genes of interest in relevant indications, in tumor, and gene expression levels of Notch activation markers, such as but not limited to Hes1, Deltex1, in tumor</measure>
    <time_frame>Baseline (study days -28 to -1)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Carboplatin/Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F: Carboplatin/Paclitaxcel and BMS-906024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Arm A: Paclitaxel + BMS-906024</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluorouracil (5FU)</intervention_name>
    <arm_group_label>Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024</arm_group_label>
    <other_name>Adrucil</other_name>
    <other_name>Carac</other_name>
    <other_name>Efudix</other_name>
    <other_name>Efudex</other_name>
    <other_name>Fluoroplex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Arm C: Carboplatin/Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_label>Arm F: Carboplatin/Paclitaxcel and BMS-906024</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024</arm_group_label>
    <other_name>Camptosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Arm C: Carboplatin/Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_label>Arm D: Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_label>Arm F: Carboplatin/Paclitaxcel and BMS-906024</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-906024</intervention_name>
    <arm_group_label>Arm A: Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_label>Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024</arm_group_label>
    <arm_group_label>Arm C: Carboplatin/Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_label>Arm D: Paclitaxel + BMS-906024</arm_group_label>
    <arm_group_label>Arm F: Carboplatin/Paclitaxcel and BMS-906024</arm_group_label>
    <other_name>Notch inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is
             considered appropriate

          -  Subjects with non-small cell lung cancer and triple-negative breast cancer are
             preferred

          -  Biopsy accessible tumor (may use archived tumor samples under certain circumstances)

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

          -  Measurable disease

        Exclusion Criteria:

          -  Uncontrolled brain metastases

          -  Infection

          -  Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory bowel
             disease)

          -  Uncontrolled or significant cardiovascular disease

          -  Subjects taking medications known to increase risk of Torsades de Pointes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Quebec</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

